Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Participants will receive 500 mg rituximab on Day 1 and Day 15

Participants will receive placebo on Day 1 and Day 15

Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.

Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).

Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.

Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.

All subjects also received a stable dose of folate (≥5 mg per week).